Compare CAL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | TRDA |
|---|---|---|
| Founded | 1878 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.1M | 404.4M |
| IPO Year | N/A | 2021 |
| Metric | CAL | TRDA |
|---|---|---|
| Price | $12.18 | $11.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 628.6K | 255.3K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $2,702,018,000.00 | $61,520,000.00 |
| Revenue This Year | $5.63 | N/A |
| Revenue Next Year | $2.16 | $3.14 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.54 | $4.93 |
| 52 Week High | $19.42 | $14.27 |
| Indicator | CAL | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 57.55 |
| Support Level | $12.03 | $10.52 |
| Resistance Level | $12.80 | $11.82 |
| Average True Range (ATR) | 0.61 | 0.74 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 10.17 | 71.93 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.